JAMA 2013-04-03
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
ABSTRACT
IMPORTANCE
There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy.
OBJECTIVE
To determine the effect of duloxetine, 60 mg daily, on average pain severity.
DESIGN, SETTING, AND PATIENTS
Randomized, double-blind, placebo-controlled crossover trial at 8 National Cancer Institute (NCI)-funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.
INTERVENTIONS
The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.
MAIN OUTCOME MEASURES
The primary hypothesis was that duloxetine would be more effective than placebo in decreasing chemotherapy-induced peripheral neuropathic pain. Pain severity was assessed using the Brief Pain Inventory-Short Form "average pain" item with 0 representing no pain and 10 representing as bad as can be imagined.
RESULTS
Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513). The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20). Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount.
CONCLUSION AND RELEVANCE
Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.
TRIAL REGISTRATION
clinicaltrials.gov Identifier: NCT00489411.
Related Questions
At what point is the neuropathy a contraindication to further bortezomib therapy?
New answer by Medical Oncologist at Winship Cancer Institute of Emory University (March 21, 2017)
Bortezomib and thalidomide cause the bulk of the neuropathy in myeloma patients worldwide, although thalidomide is rarely used in the U.S. because of more effective immune mod...
How would you manage symptoms? How would you adjust the adjuvant regimen (dose reduce, omit paclitaxel etc)? What strategies would you consider for pr...
New answer by Medical Oncologist at University of Wisconsin School of Medicine and Public Health (February 4, 2020)
CTCAE grading for peripheral motor sensory neuropathy remains a bit challenging, as Grade 1 is asymptomatic and grade 2 is already moderate (or limiting IADLs). However, I do ...